Method of deforming osteoarthrosis or osteochondrosis medical treatment

FIELD: medicine.

SUBSTANCE: invention refers to medicine and can be applied for treatment of dystrophic diseases of musculoskeletal system: deforming osteoarthrosis or osteohondrosis. Electrophoresis is applied with saline sediment of mineral water "Amurskaya-2" within 15 to 30 minutes, for 10-15 procedures. For deforming osteoarthrosis treatment current intensity is 20 - 30 mA, and for osteohondrosis treatment - 15-20 mA. Method ensures reduced treatment duration and improved quality of life for patients with musculoskeletal system diseases.

EFFECT: reduced treatment duration and improved quality of life for patients with musculoskeletal system diseases.

2 ex

 

The invention relates to medicine, namely to physiotherapy, and can be used for a comprehensive treatment of degenerative diseases of musculoskeletal system, in particular deforming osteoarthrosis (OSTEOARTHRITIS or degenerative disc disease.

It is known the use of mineral waters, therapeutic muds, sapropels for treatment of degenerative diseases of musculoskeletal system (1, 2). However, it is not known application of sludge mineral water "Amur-2" in the treatment of OSTEOARTHRITIS or osteochondrosis. Salt precipitate mineral water "Amur-2", which belongs to the far Eastern narzans, obtained by sedimentation of mineral waters taken from wells, warmed to 25° within 3 days. The difference mineraloterapiya between water taken from the well and poured into the bottle, rolled in salt precipitate.

When conducting a spectral analysis of the salt precipitate mineral water "Amur-2", obtained by sedimentation, it was found that it consists of important ions of metals: copper, Nickel, manganese, lead, mercury, zinc, cadmium, and others (3). Components of the salt precipitate mineral water "Amur-2" is represented by a complex of nutrients, permanently part of the human body and play an important biological role. In addition, components in saline sediments are biological is practical quantities and ratios, ie, those that occur in natural conditions, which determines the high efficiency of the salt sludge and eliminates the risk of overdose.

The technical result - the reduction of treatment time and improving the quality of life of patients with diseases of the musculoskeletal system, such as OSTEOARTHRITIS or osteoarthritis using raw materials of the local mineral springs.

The method of complex treatment of OSTEOARTHRITIS or degenerative disc disease, characterized in that as a therapeutic factor is used by electrophoresis salt precipitate mineral water "Amur-2"" from 15 to 30 min, the amount of 10-15 procedures with OSTEOARTHRITIS current is 20-30 mA, for osteochondrosis 15-20 mA.

We studied the efficacy of salt precipitate mineral water "Amur-2" in complex treatment in 17 patients with OSTEOARTHRITIS and in 24 patients with osteochondrosis.

The control group consisted of 20 and 15 patients, respectively, receiving conventional treatment.

Evaluated the clinical manifestations of inflammation: pain, swelling in the joints, impaired function, tonic muscle tension, biochemical indicators of activity of the process (fibrinogen, sialic acids, C-reactive protein, leukocytosis, ESR, immunological parameters, alkaline phosphatase, R-grams).

In the group of patients with OSTEOARTHRITIS on the background of the application of electrophoresis salt precipitate mineral is th water "Amur-2" is marked, an average of 5-6 days of treatment decreased pain, improved function of the joints, decreased alkaline phosphatase. No side effects were noted. The duration of hospital stay was 18 days.

Example 1.

Patient T., aged 45, was in the Department with the diagnosis: YES right knee joint. The disease duration of 5 years. Upon receipt complained of pain in the right knee joint, reinforcing when walking and in the evening, swelling, deformity of the joint, limitation of motion. In the blood: ESR - 18 mm/hour, alkaline phosphatase - 85 U/L. On the x-ray - reduced joint space, marginal osteophytes. In the complex treatment received electrophoresis salt precipitate mineral water "Amur-2". The number of procedures - 12, duration of treatment 15 min with further increase in time up to 30 minutes, the current was 20-30 mA.

On the 6th day marked decrease pain, increase range of motion, normalization of Alp.

In the control group of patients with OSTEOARTHRITIS who received traditional treatment, pain syndrome, on average, were stopped at 10-12 days, the function of the joints were recovered at 12-15 day biochemical parameters returned to normal within 15 days. The duration of hospital stay was 18 days.

In the group of patients with osteoarthritis treated in whom the integrated treatment of electrophoresis salt precipitate mineral water "Amur-2", pain, on average, were stopped on 3rd-5th day of treatment, which was accompanied by a decrease in tonic tension and improves the function of the spine.

Example 2.

Patient N., 52, was treated with a diagnosis of Osteochondrosis of the thoracic spine, aggravation. The disease duration of 3 years. Was admitted with complaints of pain in the thoracic spine, aggravated by movement. Sick for 3 years. On the x-ray - reduced the height of intervertebral disks, the growth of marginal osteophytes. In the complex treatment on the background of traditional therapy the patient was carried out electrophoresis salt precipitate mineral water "Amur-2". The number of procedures - 10, procedure duration 15 min with further increase in time up to 30 minutes, the current was 15-20 mA.

On the 4th day of application of the electrophoresis, the patient has experienced a dramatic reduction in pain, increased range of motion in the thoracic spine. The duration of hospital stay was 14 days. No side effects were noted.

The results of the study suggest that the use of salt precipitate mineral water "Amur-2" in complex treatment of degenerative diseases of musculoskeletal system by improving the function of joints, in the earlier period.

The reason for the inclusion of saline OS is dka mineral water "Amur-2" in an inpatient rehabilitation program for patients with degenerative diseases of the musculoskeletal system (OSTEOARTHRITIS or degenerative disc disease) has served as its beneficial effects on musculoskeletal system.

The technique of electrophoresis.

In the treatment of OSTEOARTHRITIS electrophoresis was carried out as follows: 2 electrode area of 600 and 400 cm3overlap the lead plates, the flannel strip and poured salt precipitate. The electrodes were applied on the front and back surface of the affected joint. Current of 20-30 mA. Procedure duration 15 min with a further increase of treatment time 30 minutes Number of 10-15 procedures.

In the treatment of osteoarthritis electrophoresis was carried out as follows: two electrode area of 600 and 400 cm3overlap the lead plates, the flannel strip and poured salt precipitate. The 1st electrode was placed on the thoracic spine, 2nd - segmental region. Current 15-20 mA. Procedure duration 15 min with a further increase of treatment time 30 minutes Number of 10-15 procedures.

Sources of information

1. The tsarfis p. g Nature and human health. - M.: Vysshaya SHKOLA, 1980, page 172-215.

2. Handbook of rehabilitation and balneology. Ed. UD Danilov, p. g a Tsarfis. - M.: Medicine, 1979, str-321.

3. The test Protocol salt precipitate mineral water "Amur-2" No. 3499 from 13.11.01, MZ the Russian Federation Centre of gossaepidnadzora in the Amur region. Accredited testing laboratory center.

Method of treatment the Oia deforming osteoarthrosis or degenerative disc disease with adjuvant therapy, characterized in that use electrophoresis salt precipitate mineral water "Amur-2" from 15 to 30 min, the number of procedures 10-15, and in deforming osteoarthrosis current is 20-30 mA, for osteochondrosis 15-20 mA.



 

Same patents:

FIELD: chemistry.

SUBSTANCE: invention relates to the formula I compounds or its pharmaceutically acceptable salt or hydrate where Z means N; X1 means O or S, R1 means alkyl containing one to six carbon atoms; R2 designates hydrogen or alkyl containing one to six carbon atoms; and R3 designates hydrogen or alkyl containing one to six carbon atoms substituted with the -ORa group where Ra means alkyl containing one to six carbon atoms; saturated nonaromatic cyclic radical containing 3 to 8 atoms in a cycle where one atom in a cycle is a heteroatom selected from N or O, whereas the rest of the atoms in the cycle are carbon atoms, one or two of these carbon atoms being not necessarily substituted by nitrogen atom with the groups -C(O)(C1-C6alcoxy) or -SO2-C1C6alkyl. Invention also relates to pharmaceutical composition.

EFFECT: compounds possess inhibiting activity.

13 cl, 1 tbl, 8 ex

FIELD: medicine; pharmacology.

SUBSTANCE: invention relates to the novel compounds with formula (I) and their pharmaceutically acceptable salts. The compounds of this invention has the properties of the NPY receptor antagonists and can be used fortreatment of such diseases as arthritis, diabetes, malnutrition, obesity. In general formula (I) , R1 means phenyl or 6-term nitrogen-containing heteroaryl, where in at least one of two meta-positions each phenyl group or 6-term nitrogen-containing heteroaryl group is substituted by group R5; R2 means hydrogen; R3 means C3-C6cycloalkyl, naphthyl, phenyl or 5-6-term heteroaryl, containing N or S as heteroatoms, where in at least one of two ortho-positions each group of C3-C6 cycloalkyl, naphthyl, phenyl or 5-6-term heteroaryl, containing N or S as heteroatoms, substituted by group R6; R4 means hydrogen, C1-C6alkyl; R5 means hydrogen, cyano, trifluoromethyl, C1-C6alkyl-SO2-, amino-SO2-, halogen, C1-C6alcoxy, C1-C6alkylcarbonil or aminocarbonil; R6 means hydrogen, halogen, cyano, nitro, trifluoromethyl, C1-C6 alkyl, C1-C6 alcoxy or hydroxy, provided, one R5 group, and R6 doesn't mean hydrogen.

EFFECT: described compounds and based on them pharmaceutical agents are efficient in treatment and prevention of above listed diseases.

19 cl, 2 tbl, 2 dwg, 130 ex

FIELD: medicine; pharmacology.

SUBSTANCE: invention relates to the method of treatment of diseases caused by abnormality of cartilaginous and/or bone tissue; the method includes the treatment course of applications of hydrolysed collagen and cosmetic clay to the painful area, when the KollAmin-80 or Epydermat-0 are rubbed into the painful area, and then the diluted cosmetic clay is applied, the area is covered with the polyethylene film or compressor paper and warmth-keeping for 30-40 min once daily, with course of 30-60 days 3-6 times annually.

EFFECT: high therapeutic efficiency is achieved.

2 cl, 9 ex

FIELD: medicine.

SUBSTANCE: preparation has mixture of collagen I and collagen II taken approximately in 1:19 to 19:1 proportion, respectively. The matrix is usable as supporting implant for restructuring cartilage of vertebral column or meniscus.

EFFECT: stimulated injured cartilage recovery.

19 cl, 2 dwg, 1 tbl

FIELD: medicine, pharmaceutical industry.

SUBSTANCE: invention represents a drug of the following composition, wt.-%: chondroitin sulfate, 1.0-10.0; sodium diclofenac, 1.0-10.0; dimethylsulfoxide, 5.0-25.0, and ointment base, the balance. Ointment base represents pentol, stearic acid, vaseline, lanolin and water, polymeric-base gel, or polyethylene oxides. Proposed drug possesses the combined effect.

EFFECT: improved and valuable medicinal properties of agent.

2 cl, 1 tbl, 3 ex

FIELD: organic chemistry, medicine, pharmacy.

SUBSTANCE: invention relates to novel compounds of the formula (I): and their pharmaceutically acceptable salts and esters wherein R1 means phenyl, naphthyl, 5-6-membered heterocyclyl comprising oxygen (O), nitrogen (N) or sulfur atom (S) as heteroatoms and wherein phenyl, naphthyl and heterocyclyl are optionally substituted with 1-3 substitutes chosen from halogen atom, (C1-C6)-alkyl, (C1-C6)-alkoxy, halogen-(C1-C6)-alkyl, halogen-(C1-C6)-alkoxy, nitro; di-(C1-C6)-alkylamino or (C1-C6)-alkoxy groups; R2 means hydrogen atom; R3 means (C1-C6)-alkyl or trifluoromethyl; A1 means C-R3 or nitrogen atom; A2 means piperidine or pyrrolidine wherein nitrogen atom in piperidine or pyrrolidine ring is added to A3 wherein A3 means -S(O)2- or -C(O)-; n = 0, 1 or 2. Also, invention relates to a pharmaceutical composition based on compounds proposed by the invention. Proposed compounds possess properties of NPY receptors antagonists and can be used in treatment arthritis, diabetes mellitus, nutrition disorders, obesity and others.

EFFECT: valuable medicinal properties of compounds and pharmaceutical composition.

16 cl, 1 tbl, 1 dwg, 26 ex

FIELD: medicine.

SUBSTANCE: invention relates to biomaterials and can be used in plastic surgery and stomatology in conservative treatment. Proposed material based on calcium inorganic phosphates comprises additionally calcium carbonate wherein it comprises chlorapatite, calcium and iron phosphate hydrate, calcium - iron phosphate and calcium hydrogen phosphate as calcium inorganic phosphates, and these components are taken in the definite ratio. The more ratio Fe/Ca is 0.02-0.06, and dispersed composition of the main fraction is in the range 5-40 mcm. Proposed material for medicinal using is biocompatible with living body tissues completely, it possesses transdermal activity, analgesic effect and ability for repairing and strengthening osseous tissues, and to relieve and strength dental enamel in stomatology.

EFFECT: valuable medicinal properties of material.

3 cl, 3 dwg

FIELD: organic chemistry, medicine, pharmacy.

SUBSTANCE: invention relates to heterocycle-substituted tricyclic compounds of the formula (I): or their pharmaceutically acceptable salts wherein R means hydrogen atom; R1 and R2 are chosen independently from group comprising hydrogen atom or alkyl comprising 1-6 carbon atoms; R3 means hydrogen atom; n1 and n2 = 0-3 independently under condition that they both do not mean 0; Het means pyridyl wherein pyridyl is added to B through cyclic carbon atom and it comprises from 1 to 4 substitutes (W) chosen independently from group comprising -NR4R5, -NHCOR26, -NHSO2R16; R21 means aryl and R21 means heteroaryl wherein heteroaryl represents furyl, thienyl, pyridyl, thiazolyl, pyrrolidinyl, azethidinyl; R4 and R5 mean hydrogen atom or alkyl comprising 1-6 carbon atoms, or R4 and R5 mean in common -(CH2)3-, -(CH2)4-, -(CH2)5- or -(CH2)2NR7-(CH2)2- wherein R7 means hydrogen atom or alkyl comprising 1-6 carbon atoms; R8, R, R10 and R11 mean hydrogen atom; B means -(CH2)n4CR12=CR12a(CH2)n5 wherein n4 and n5 = 0-2 independently; R12 and R12a are chosen independently from group comprising hydrogen atom or alkyl comprising 1-6 carbon atoms; R21 means from 1 to 3 substitutes chosen independently from group comprising hydrogen atom, trifluoromethyl, trifluoromethoxy, halogen atom, cyano, alkyl comprising 1-6 carbon atoms, alkoxy group comprising 1-6 carbon atoms, or -CR29(=NOR28); R22 means -COR23, -S(O)R31, -S(O)2R31 or -COOR27; R23 means cycloalkyl comprising 3-7 carbon atoms, (C3-C7)-cycloalkyl-(C1-C6)-alkyl, cycloalkyl comprising 3-7 carbon atoms containing from 1 to 3 substitutes chosen from group comprising halogen atom, (C1-C3)-alkoxy-(C1-C3)-alkyl, hydroxy group and alkoxy group comprising 1-6 carbon atoms, aryl, aryl-(C2-C6)-alkyl; R27 means alkyl comprising 1-6 carbon atoms, phenyl or benzyl; R28 and R29 are chosen independently from group comprising hydrogen atom or alkyl comprising 1-6 carbon atoms; R31 means alkyl comprising 1-6 carbon atoms, halogenalkyl comprising 1-6 carbon atoms, aryl, aryl-(C1-C6)-alkyl. Also, invention relates to pharmaceutical compositions containing these substances and their using for preparing a drug used in treatment of thrombosis, atherosclerosis, restenosis, hypertension, stenocardia, arrhythmia, heart failure and cancer.

EFFECT: valuable medicinal properties of compounds and pharmaceutical composition.

10 cl, 11 tbl, 9 ex

FIELD: medicine.

SUBSTANCE: the present innovation deals with treating and preventing the loss of bony tissue and/or increased development of bony tissue. For this purpose it is necessary to apply 15-lipoxygenase inhibitors. These molecules could be introduced either individually or in combination with agents that inhibit the resorption of bony tissue or additional agents that regulate calcium resorption out of bony tissue or increase the accumulation of bony tissue. The innovation enables to widen the assortment of medicinal preparations for treating diseases associated with the loss of bony tissue, such as osteoporosis, osteoarthritis, Paget's disease and those of periodontium and, also, the fractures.

EFFECT: higher efficiency of therapy.

16 cl, 9 dwg, 7 ex, 5 tbl

FIELD: organic chemistry, medicine, pharmacy.

SUBSTANCE: invention describes derivatives of benzonaphthoazulene of the formula (I): wherein X represents oxygen (O) or sulfur (S) atom; Y and Z mean hydrogen atom; groups of the formula or the formula mean structures of formulae ; R1 represents compound of the formula (II): wherein R2 and R3 can represent simultaneously and independently of one another hydrogen atom (H), (C1-C4)-alkyl, or in common with nitrogen atom (N) they mean heterocycle chosen from morpholinyl, piperidinyl or pyrrolidinyl; n means a whole number from 0 to 3; m means a whole number 1; Q1 and Q2 represent independently of one another oxygen atom or group of the formula: wherein y1 and y2 represent independently of one another hydrogen atom or (C1-C4)-alkyl. Also, invention describes derivatives of benzonaphthoazulene of the formula (Ia) given in the invention description and differing from compounds of the formula (I) wherein R1 represents (C1-C7)-alkyl substituted with hydroxyl or (C1-C7)-alkyloxycarbonyl. Compounds of the formula (I) inhibit producing TNF-α, and compounds of the formula (Ia) are intermediate substances used in synthesis of compounds of the formula (I). Also, invention describes using compounds of the formula (Ia) wherein R1 means CO2Et, CH2OH for preparing compounds of the formula (I), and using compounds of the formula (I) for preparing pharmaceutical compositions designated for inhibition of production of TNF-α.

EFFECT: valuable properties of compounds and pharmaceutical compositions.

10 cl, 5 tbl, 10 ex

FIELD: medicine.

SUBSTANCE: target goal is resolved by combined therapy, which consists of 2 stages: out-patient home-based treatment and in-patient treatment at sanatorium-and-spa. The second stage starts immediately after the first one is completed. At the first stage, the oxygen and the blood supplies of the central nervous system, cerebral cortex, optic tract, anterior eye segment. During the second stage at sanatorium-and-spa, the therapy proper of myopia and amblyopia is performed by use of medicamentous, physical and electrophysiological methods. Irifrin, Arutimol, Vasobral, Mydriacyl and Catachrome are used in medicamentous therapy.

EFFECT: visual acuity is improved and long-term preservation is achieved.

5 cl, 1 tbl, 4 ex

FIELD: medicine; medical engineering.

SUBSTANCE: device has thin flexible plaster having at least two electrodes, power supply source and separator. The separator has conducting composition covering one of electrodes. At least one variable parameter of power supply source, composition and separator is predefined and preset. The plaster is used for treating skin diseases and/or patient skin derivate.

EFFECT: wide range of applications; drug delivery simplicity and effectiveness.

69 cl, 6 dwg, 2 tbl

FIELD: medicine.

SUBSTANCE: method involves prescribing conservative training motor activity and feeding diet No 5 with low mineralization low carbonic acid concentration sulfate and hydrocarbonate sodium-calcium mineral water being taken. Mineral water baths with low mineralization low carbonic acid concentration sulfate and hydrocarbonate sodium-calcium mineral water are given at 36-37°C during 12-15 min with 8-10 procedures per treatment course. 2.5% succinic acid solution electrophoresis is additionally applied to interscapular zone from cathode with the other washer - anode being placed on liver and right hypochondrium projection zone using current of 15-25 mA during 15-25 min daily with 10-12 procedures per treatment course.

EFFECT: reduced intensity of digestion disorder syndrome manifestation; stabilized peroxide homeostasis; increased organism adaptation capability.

5 tbl

FIELD: medicine, medicinal equipment.

SUBSTANCE: the present innovation deals with devices and methods for perosseous and/or intraosseous injection of medicinal substances. The kit for delivering electric current and/or voltage to a part of skin and/or for perosseous or intraosseous injection of substances contains a cutaneous applicator that contains a power pack and, at least, two electrodes being electrically connected with the power pack and indicated for electric connection with a patient's part of skin and, at least, one separator for keeping electroconductive flowing medium. The latter is indicated to be applied onto, at lest, one electrode and/or locally applied onto a patient's part of skin. In one variant, a thin elastic cutaneous applicator has got a thin elastic power pack and thin chamber that contains electroconductive flowing medium/composition, in which a thin chamber is located in, at least, one mentioned negative electrode and, at least, on one positive electrode. The innovation enables to increase the universality of cutaneous applicators due to introducing any desired number of substances in any desired dosages.

EFFECT: higher efficiency.

85 cl, 6 dwg

FIELD: medicine.

SUBSTANCE: method involves applying therapy course containing iodine-bromine baths and vaginal irrigations given every other day. Electrophoresis is administered in days free of baths and irrigations after 2 adaptation days with silt mud enriched in hydrogen sulfide water containing hydrogen sulfide in concentration of 350 mg/l. The treatment is applied to hypogastric and lumbosacral region at the level of L4-S2 vertebrae. Electric current intensity is equal to 0.05-0.1 MA/cm2 during 20 min. The total treatment course is 8 balneo- and physioprocedures long.

EFFECT: reduced peritoneal commissure process intensity; normalized vegetative nervous system and ovarian functions; improved cellular and humoral immunity; increased female fertility.

5 tbl

FIELD: medicine.

SUBSTANCE: method involves placing three circular electrodes of different area so that the smaller two are placed on orbital and upper eyelids region skin when eyes are closed. They are connected with split wire to an electrode of greater area that is placed in cervico-occipital region of patient head. Injured regions electrophoresis is carried out with 1.5% Neuromidine solution according to ophthalmo-occipital method placing patient in dorsal position. Current is supplied to light pricking sensation under the electrodes. Given current intensity is controlled over the treatment time. Procedure duration is 15-20 min and treatment course is 15 daily sessions long.

EFFECT: enhanced effectiveness in treating defective neuromuscular eyeball synapses and nuclear structures of oculomotor nerves.

2 cl

FIELD: medicine.

SUBSTANCE: in pre-surgical period one should introduce Collagenase CC due to electrophoresis onto anterior abdominal wall in area of adhesive process. After abdominal cavitary sanitation and the main stages of operation it is necessary to introduce 500 mg Collagenase CC 250 U dissolved in 100 ml physiological solution into area of deserosed intestine. The innovation prevents the relapse of adhesions.

EFFECT: higher efficiency of therapy.

2 ex, 1 tbl

Needle electrode // 2308985

FIELD: medical equipment.

SUBSTANCE: therapeutic needle electrode, used for through-skin galvanic therapy of tumors, can be used for visualization due to methods of forming image; it is made of titanium. Electrode has coating made of platinum; coating is applied by method condensation from vapor phase. Excluding end area of needle, electrode is covered with electrical insulating polymer.

EFFECT: reduced costs; higher strength of electrode; prevention of traumatism of tissues.

15 cl, 1 tbl, 1 ex

FIELD: medicine.

SUBSTANCE: method involves making local 5% aminocaproic acid injection into periocular tissues in the amount of 1.0 ml. Then, bath electrophoresis is carried out 1-2 h later in hyphaema cases. Endonasal electrophoresis is applied in hemophthalm cases and eye fundus hemorrhages with proteolytic enzymes like 0.2% trypsin and chemotrypsin solution for 15-20 min with current intensity of 1.5 mA. Intravenous infusion of 100 ml of 0.03% sodium hypochlorate solution is carried out once or twice a day with the number of injections equal to 2-3 in hyphaema cases and 3-5 injections in hemophthalm and hemorrhages cases.

EFFECT: high accuracy of early stage diagnosis.

FIELD: physiotherapy.

SUBSTANCE: method comprises sparing or sparing and training regimen of motion activity, special diet (number 5), oral administration of low-mineralized and low-carbonized calcium-sodium sulfate-hydrocarbonate mineral water and performance of low-carbonized calcium-sodium sulfate-hydrocarbonate mineral baths. Additionally, electrophoresis with 2% succinic acid solution is effected for 15-20 min on trigeminal nerve innervation region in the form of half-mask. Treatment of the left and right halves of the face are alternated. Treatment course comprises 12 procedures.

EFFECT: improved energetic exchange and adaptation processes.

1 tbl, 2 ex

FIELD: medicine.

SUBSTANCE: method involves prescribing conservative training motor activity and feeding diet No 5 with low mineralization low carbonic acid concentration sulfate and hydrocarbonate sodium-calcium mineral water being taken. Mineral water baths with low mineralization low carbonic acid concentration sulfate and hydrocarbonate sodium-calcium mineral water are given at 36-37°C during 12-15 min with 8-10 procedures per treatment course. 2.5% succinic acid solution electrophoresis is additionally applied to interscapular zone from cathode with the other washer - anode being placed on liver and right hypochondrium projection zone using current of 15-25 mA during 15-25 min daily with 10-12 procedures per treatment course.

EFFECT: reduced intensity of digestion disorder syndrome manifestation; stabilized peroxide homeostasis; increased organism adaptation capability.

5 tbl

Up!